Best of ASCO - 2014 Annual Meeting

 

Welcome

Adjuvant Therapy

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Adjuvant chemotherapy for pathological stage I non-small cell lung cancer with high-risk factors for recurrence: A multicenter study.

Yasuhiro Tsutani

8500

ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).

Benjamin J. Solomon

TPS8569

Association of PD-L1 protein expression and TMB in non-small cell lung cancer.

Yaru Chen

e20009

CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC).

Edward B. Garon

TPS8570

Comparison of preoperative and prechemotherapy lymphocyte counts to predict outcome of non-small cell lung cancer patients treated with adjuvant chemotherapy.

Hyun Woo Lee

e20002

Evaluation of tumor infiltrating lymphocites (TILs) and survival in patients with resected non-small cell lung cancer.

Nuria Cárdenas Quesada

e20010

Impact of decision-support system and guideline treatment concordance on response rate in advanced lung cancer.

Jun Liang

e20006

LUNG cancer in Lleida: An epidemiologic study.

Juan Felipe Cordoba

e20003

Phase II, prospective single-arm study of adjuvant pembrolizumab in N2 positive non-small cell lung cancer (NSCLC) treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection: Preliminary results.

Myung-Ju Ahn

8520

Primary tumor location as an important predictor for survival in pulmonary adenocarcinoma.

Zhe Wang

e20000

Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.

Jamie E. Chaft

8507

Randomized phase III study of pemetrexed/cisplatin (Pem/Cis) versus vinorelbine /cisplatin (Vnr/Cis) for completely resected stage II-IIIA non-squamous non-small-cell lung cancer (Ns-NSCLC): The JIPANG study.

Hirotsugu Kenmotsu

8501

Refining the role of adjuvant chemotherapy in stage IB and IIA NSCLC.

Ranjan Pathak

8519

The role of EGFR inhibitors as adjuvant therapy for EGFR mutation positive non-small cell lung cancer.

Peng Xie

8508

The tumor microenvironment in EGFR-driven loco-regional lung adenocarcinoma can predict higher risk of recurrence.

Maya Khalil

8521

TTF1 negative in non small cell lung cancer adenocarcinoma: A prognostic factor.

Juan Felipe Cordoba

e20004